Why the study?
Does the risk of stroke increase significantly between ages 66 and 74 in men and women with atrial fibrillation and no other CHA2DS2-VASc risk factors who are not on anticoagulation therapy?
Does the risk of stroke increase significantly between ages 66 and 74 in men and women with atrial fibrillation and no other CHA2DS2-VASc risk factors who are not on anticoagulation therapy?
The risk of stroke more than doubles between ages 66 and 74 in AF patients with no other risk factors, suggesting a greater net clinical benefit of anticoagulation for the older individuals in this specific age bracket.
May inform anticoagulation thresholds for older low-risk AF patients; leaves open need for randomized confirmation of net benefit.
The risk of stroke more than doubled in this study as men and women with AF but no other CHA2DS2-VASc risk factors aged from 66 to 74 years. These data suggest that anticoagulation therapy is more likely to benefit older individuals within this group of patients, whereas younger individuals are less likely to gain net clinical benefit from anticoagulation therapy.
No takes yet. Share an insight, caveat, or question.
Abdel‐Qadir et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: